SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Atkins MB. The treatment of metastatic melanoma with chemotherapy and biologics. Curr Opin Oncol. 1997; 9: 205213.
  • 2
    Coates AS, Segelov E. Long term response to chemotherapy in patients with visceral metastatic melanoma. Ann Oncol. 1994; 5: 249251.
  • 3
    Balch CM, Reintgen DS, Kirkwood JM, et al. Cutaneous melanoma. In: DeVitaVTJr, HellmanS, RosenberSA, eds. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia, Pa: Lippincott-Raven; 1997: 19471994.
  • 4
    Falkson CI, Ibrahim J, Kirkwood JM, et al. Phase III trial of dacarbazine versus dacarbazine with tamoxifen versus dacarbazine with interferon alfa-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1998; 16: 17431751.
  • 5
    Middleton M, Grob J, Aaronson N, et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000; 18: 158166.
  • 6
    Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a Phase II study. J Clin Oncol. 2004; 15:22: 1118–1125.
  • 7
    Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006; 24: 47384745.
  • 8
    Eggermont AMM, Kirkwood JM. Re-evaluating of the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer. 2004; 40: 18251836.
  • 9
    Bafaloukos D, Aravantinos G, Fountzilas G, et al. Docetaxel in combination with dacarbazine (DTIC) in patients with advanced melanoma: a Phase II study of the Hellenic Cooperative Oncology Group. Oncology. 2002; 63: 333337.
  • 10
    Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCR 81045: m&B 39831: NSC 362856). Br J Cancer. 1992; 65: 287291.
  • 11
    Bleehen NM, Newlands ES, Lee SM, et al. Cancer Research Campaign Phase II trial of temozolomide in metastatic melanoma. J Clin Oncol. 1995; 13: 910913.
  • 12
    Lee SM, Thatcher N, Margison GP. O6-alkylguanine-DNA alkyltrasferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res. 1991; 51: 619623.
  • 13
    Tawbi H, Tarhini A, Moschos S, et al. Phase I trial of lomeguatrib (PN) combined with dacarbazine (DTIC) for treatment of patients with melanoma and other solid tumors: initial results. 2006 ASCO Annual Meeting Proceedings. J Clin Oncol. 2006; 24( suppl):18S. Abstract 8016.
  • 14
    Plummer R, Lorigan Evans J, et al. First and final report of a Phase II study of the poly-(ADP-ribosed) polymerase (PARR) inhibitor, AGO14699 in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). 2006 ASCO Annual Meeting Proceedings. J Clin Oncol. 2006; 24( suppl): 18S. Abstract 8013.
  • 15
    Kirkwood JM, Agarwala S. Systemic cytotoxic and biologic therapy of melanoma. In: DeVitaVT, HellmanS, RosenbergSA, eds. PPO Updates. Vol 7. Philadelphia, Pa: Lippincott; 1993: 1.
  • 16
    Glover D, Glick JH, Weiler C, et al. WR2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol. 1987; 5: 574578.
  • 17
    Glover D, Ibrahim J, Kirkwood J, et al. Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). Melanoma Res. 2003; 13: 619626.
  • 18
    Evans LM, Casper ES, Rosenbluth R. Participating community oncology program investigators: Phase II trial of carboplatin in advanced malignant melanoma. Cancer Treat Rep. 1987: 71: 171172.
  • 19
    Mohammed MQ, Retsas S. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin. Anticancer Drugs. 2000; 11: 859863.
  • 20
    Lutzky J, Nunez Y, Graham P. A Phase II trial of oxaliplatin in patients with advanced melanoma. 2006 ASCO Annual Meeting Proceedings (Post-meeting Edition). J Clin Oncol. 2006; 24( suppl): 18S. Abstract 18016.
  • 21
    Boaziz C, Breau JL, Morere JF, et al. Brain metastases of malignant melanoma. Bull Cancer. 1991; 78: 347353.
  • 22
    Jacquillat C, Khayat D, Banzer P, et al. Final report of the French multicentric Phase II study of the nitrosurea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer. 1990; 66: 18731878,
  • 23
    Calabresi E, Aapro M, Becquart D, et al. Multicenter Phase II trial of the single fotemustine in patients with advanced malignant melanoma. Ann Oncol. 1991; 2: 377378.
  • 24
    Retsas S. International Phase II clinical study of S10036 (fotemustine) as single agent by intravenous administration in treatment of metastatic malignant melanoma. Confirmatory study in Great Britain. Data from Servier Internal Report NP 1478, France.
  • 25
    Kleeberg UR, Engel E, Israels P, et al. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicenter Phase II trial of the EORTC Melanoma Cooperative Group (MCG). Melanoma Res. 1995; 5: 195200.
  • 26
    Shallreuter KU, Wenzel E, Brassow FW, et al. Positive Phase II study in the treatment of advanced malignant melanoma with fotemustine. Cancer Chemother Pharmacol. 1991; 29: 167171.
  • 27
    Quagliana JM, Stephens M, Baker P, et al. Vindesine in patients with metastatic malignant melanoma. A Southwest Oncology Group study. J Clin Oncol. 1984; 4: 316319.
  • 28
    Einzig AI, Hochester H, Wiernik PH, et al. A Phase II study of Taxol in patients with malignant melanoma. Invest New Drugs. 1991; 9: 5964.
  • 29
    Bedikian AY, Weiss GR, Legha SS, et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol. 1995; 13: 28592899.
  • 30
    Aamdal S, Wolff I, Kaplan S, et al. Docetaxel (Taxotere) in advanced malignant melanoma: a Phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer. 1994; 30A: 10611064.
  • 31
    Hersh E, O'Day S, Gonzales R, et al. Phase II trial of ABI-007 (Abraxane) in previously treated and chemotherapy naive patients with metastatic melanoma. Melanoma Res. 2006; 16: S78. Abstract ABS-0141.
  • 32
    Costanza M, Nathanson L, Schoenfeld D, et al. Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer. 1997; 40: 10101015.
  • 33
    Avril MF, Bonneterre J, Delaunay M, et al. Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group. Cancer Chemother Pharmacol. 1990; 27: 8184.
  • 34
    Costanzi JJ, Vaitkevicius VK, Quagliana JM, et al. Combination chemotherapy for disseminated malignant melanoma. Cancer. 1975; 35: 342346.
  • 35
    Fletcher WS, Green S, Fletcher JR, et al. Evaluation of cis-platinum and DTIC combination chemotherapy in disseminated melanoma. A Southwest Oncology Group Study. Am J Clin Oncol. 1988; 11: 589593.
  • 36
    Vorobiof DA, Sarli R, Falkson G. Combination chemotherapy with dacarbazine and vindesine in the treatment of metastatic malignant melanoma. Cancer Treat Rep. 1986; 70: 927928.
  • 37
    Legha SS, Ring S, Papadopoulos N, et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine and DTIC (CVD) for metastatic melanoma. Cancer. 1989; 64: 20242029.
  • 38
    Buzaid AC, Legha SS, Winn R, et al. Cicplatin (C), vinblastine (V), and dacarbazine (D) (CVD) versus dacarbazine alone in metastatic melanoma: preliminary results of a Phase II Cancer Community Oncology Program (CCOP) trial [abstract]. Proc Am Soc Clin Oncol. 1993; 12: 389a.
  • 39
    Del Prete SA, Maurer LH, O'Donnell J. Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat Rep. 1984; 69: 14031405.
  • 40
    Lattanzi SC, Tosteson T, Chertoff J, et al. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res. 1995; 5: 365369.
  • 41
    Rusthoven JJ, Quirt IC, Iscoe NA, et al. Randomized, double-blind placebo-controlled trial comparing the response rates of carmustine, dacarbazine and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol. 1996; 14: 20832090.
  • 42
    Chapman PB, Einhorn L, Meyers ML, et al. Phase III multicenter randomized trial of Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999; 17: 27452761.
  • 43
    Cocconi G, Bella M, Calabresi F, et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med. 1992; 327: 516523.
  • 44
    Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol. 1991; 9: 14031408.
  • 45
    Lens MB, Relman T, Husain AF. Use of tamoxifen in the treatment of malignant melanoma. Systematic review and metaanalysis of randomized controlled trial. Cancer. 2003; 98: 13551361.
  • 46
    Flaherty LE, Liu PY, Unger J, Sondak VK. Comparison of patient characteristics and outcome between a single-institution Phase II trial and a cooperative-group Phase II trial with identical eligibility in metastatic melanoma. Am J Clin Oncol. 1997; 20: 600604.
  • 47
    Hwu WJ, Krown SE, Menell JH, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol. 2003; 21: 33513356.
  • 48
    Atkins MB, Sosman J, Agarwala S, et al. A Cytokine Working Group Phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol. 2005; 23( suppl): 16S. Abstract 7552.
  • 49
    Flaherty LE, Robinson W, Redman BG, et al. A Phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer. 1993; 71: 35203525.
  • 50
    Atkins MB, O' Boyle KR, Sosma JA, et al. Multiinstitutional Phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol. 1994; 12: 15531560.
  • 51
    Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol. 1998; 16: 17521759.
  • 52
    O'Day S, Gammon G, Boasberg P, et al. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor and tamoxifen for patients with metastatic melanoma. J Clin Oncol. 1999; 17: 27522761.
  • 53
    Flaherty L, Atkins M, Sosman J, et al. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two Phase II cytokine working group trials. J Clin Oncol. 2001; 19: 31943202.
  • 54
    Keilholz U, Conradt C, Legha SS, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol. 1998; 16: 29212929.
  • 55
    Allen IE, Kupelnick B, Kumashiro M. Efficacy of interleukin-2 in the treatment of metastatic melanoma—systematic review and meta-analysis. Cancer Ther. 1998; 1: 168173.
  • 56
    Keilholz U, Goey SH, Punt CJA, et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma. A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol. 1997; 15: 25792588.
  • 57
    Keilholz U, Punt CJ, Gore M, et al. Dacarbazine, cisplatin and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized Phase III trial (18951) of the European Organization for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2005; 23: 67476755.
  • 58
    Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol. 1999; 17: 968975.
  • 59
    Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma.: results from a Phase III randomized trial. J Clin Oncol. 2002; 20: 20452052.
  • 60
    Atkins MB, Lee S, Flaherty LE, et al. A prospective randomized Phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695). An ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol. 2003; 22: 708. Abstract 2847.
  • 61
    Wilhelm SM, Carter C, Tang L, et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64: 70997109.
  • 62
    Karasarides M, Chiloeches A, Hayward R, et al. B-RAF is a therapeutic target in melanoma. Oncogene. 2004; 23: 62926298.
  • 63
    Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43–9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005; 23: 965972.
  • 64
    Ahmad T, Marais R, Pyle L, et al. BAY 43-9006 in patients with advanced melanoma: the Royal Marsden experience. 2004 ASCO Annual Meeting Proceedings (Post-meeting Edition). J Clin Oncol. 2004; 22( suppl): 14S. Abstract 7506.
  • 65
    Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006; 95: 581586.
  • 66
    Flaherty KT, Brose M, Schucter L, et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. 2004 ASCO Annual Meeting Proceedings (Post-meeting Edition). J Clin Oncol. 2004; 22( suppl): 14S. Abstract 7507.
  • 67
    Zimpfer Rechner C, Hofmann U, Figl R, et al. Randomized Phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicenter trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res. 2003; 13: 531536.
  • 68
    Hodi FS, Soiffer RJ, Clark J, et al. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol. 2002; 25: 283286.
  • 69
    Amaravadi RK, Schucter LM, Kramer A, et al. Preliminary results of a randomized Phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol. 2006; 24( suppl): 18S. Abstract 8009.
  • 70
    Tchekmedyian S, Glasby J, Korman A, et al. MDX-010 (human anti-CTLA4): a Phase I trial in malignant melanoma [abstract]. Proc Am Soc Clin Oncol. 2002; 21: A56.
  • 71
    Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a Phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005; 23: 89688977.
  • 72
    Hersh EM, Weber J, Powderly J, et al. A Phase II, randomized multi-center study of MDX-010 alone or in combination with dacarbazine (DTIC) in stage IV metastatic malignant melanoma. 2004 ASCO Annual Meeting Proceedings (Post-meeting Edition). J Clin Oncol. 2004; 22( suppl): 14S. Abstract 7511.
  • 73
    Fischkoff SA, Hersh E, Weber J, et al. Durable responses and long-term progression-free survival observed in a Phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. Proc Am Soc Clin Oncol 2005; 23: 716S. Abstract 7525.
  • 74
    Eggermont A. Reaching first base in the treatment of metastatic melanoma [editorial]. J Clin Oncol. 2006; 24: 4673.
  • 75
    Van Belle PA, Elenitsas R, Satyamoorthy K, et al. Progression-related expression of β3 integrin in melanomas and nevi. Hum Pathol. 1999; 33: 562567.
  • 76
    Mitjans F, Meyer T, Fittschen C, et al. In vivo therapy of malignant melanoma by means of antagonists of aV integrins. Int J Cancer. 2000; 87: 716723.
  • 77
    Hersey P, Sosman J, O'Day S, et al. A Phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human metastatic melanoma (MM). Proc Am Soc Clin Oncol. 2005; 23: 711S. Abstract 7507.
  • 78
    Ridolfi R, Chiarion-Silenti V, Guida M, et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter Phase III randomized clinical trial. J Clin Oncol. 2002; 20: 16001607.
  • 79
    Dorval T, Negrier S, Chevreau C, et al. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-a-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Luttle Contre le Cancer multicenter, parallel study. Cancer. 1999; 85: 10601066.